Nephros Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Nephros in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Nephros stock.
View analyst ratings for Nephros or view top-rated stocks.

Wall Street analysts have given Nephros a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Nephros wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Nephros saw a decline in short interest in the month of July. As of July 15th, there was short interest totaling 17,300 shares, a decline of 44.7% from the June 30th total of 31,300 shares. Based on an average trading volume of 10,200 shares, the short-interest ratio is currently 1.7 days. Approximately 0.2% of the company's stock are short sold.
View Nephros' Short Interest.

Nephros is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Nephros.

Nephros, Inc. (NASDAQ:NEPH) announced its quarterly earnings data on Thursday, May, 6th. The company reported ($0.06) EPS for the quarter, beating analysts' consensus estimates of ($0.14) by $0.08. The business earned $2.74 million during the quarter, compared to analysts' expectations of $2.70 million. Nephros had a negative net margin of 47.27% and a negative trailing twelve-month return on equity of 30.24%.
View Nephros' earnings history.

Nephros issued an update on its second quarter 2021 earnings guidance on Thursday, July, 22nd. The company provided EPS guidance of for the period. The company issued revenue guidance of $2.20 million-$2.20 million, compared to the consensus revenue estimate of $2.80 million.

3 equities research analysts have issued twelve-month target prices for Nephros' shares. Their forecasts range from $12.50 to $16.00. On average, they expect Nephros' stock price to reach $13.83 in the next year.
View analysts' price targets for Nephros or view top-rated stocks among Wall Street analysts.

Some companies that are related to Nephros include Neuronetics (STIM), Cytosorbents (CTSO), Utah Medical Products (UTMD), Apyx Medical (APYX), TransEnterix (TRXC), Profound Medical (PROF), The Westaim (WEDXF), Co-Diagnostics (CODX), DarioHealth (DRIO), TELA Bio (TELA), Apollo Endosurgery (APEN), Titan Medical (TMDI), Nemaura Medical (NMRD), Beyond Air (XAIR) and T2 Biosystems (TTOO).
View all of NEPH's competitors.

Nephros trades on the NASDAQ under the ticker symbol "NEPH."

Shares of NEPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

Nephros has a market capitalization of $0.00 and generates $8.56 million in revenue each year. The company earns $-4,770,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis.

Nephros employs 27 workers across the globe.

The official website for Nephros is www.nephros.com.

Nephros is headquartered at 380 LACKAWANNA PLACE, SOUTH ORANGE NJ, 07079.

Nephros' mailing address is 380 LACKAWANNA PLACE, SOUTH ORANGE NJ, 07079. The company can be reached via phone at 201 343 5202 or via email at [email protected]